Denise Myshko

New research finds that in 2022, U.S. prices across all drugs were almost three times higher than in other countries.

Biogen has stopped its confirmatory trial of Aduhelm and will direct resources toward Leqembi and the research of other treatments for Alzheimer’s disease.

Biogen will focus its resources on Leqembi and research of other treatments for Alzheimer’s disease.

CVS Caremark, however, will continue to manage specialty drug benefits for Tyson Foods.

CVS Caremark will continue to manage specialty drug benefits for Tyson Foods.

Joseph M. Shields talks about the formation of Transparency-Rx and its goals of achieving PBM reform that focuses on “corrective steps to address the misalignment in the marketplace to ensure that there’s competition and choice.”

Coverage of contraceptives and contraceptive care without cost-sharing is required under the Affordable Care Act.

Current treatments for urea cycle disorders, which causes ammonia to build up in the blood, have a bitter taste and smell. Pheburane was developed with a special coating that masks the taste of sodium phenylbutyrate. It has a list price of $4,375 per bottle.

Peter Rubin of No Patient Left Behind worries that patients may not see benefits, either in lowered costs or continued investment in new therapies, from drug price negotiations required under the Inflation Reduction Act.

Last year saw the approval of several firsts, including the first vaccines to prevent respiratory syncytial virus in older adults and infants and a first vaccine to prevent the mosquito-borne virus chikungunya.

A 2020 rule stands in which copay assistance from pharmaceutical companies counts toward deductibles for brand name drugs without a generic competition.

The digital prescription therapeutic AspyreRx, when added to prescription diabetes therapies, can help reduce the costs of managing the disease.

Last year saw the approval of several firsts, including the first vaccines to prevent respiratory syncytial virus in older adults and infants and a first vaccine to prevent the mosquito-borne virus chikungunya.

UnitedHealth Group executives attribute the increase of revenue at Optum Rx to the addition of new clients, expanded relationships with existing clients, and advancements in services.

UnitedHealth Group executives attribute the increase in revenue and earnings to growth at both its Optum and UnitedHealthcare divisions.

Clients are cautious about how the cost in “cost-plus” programs is determined, how rebates factor in and the benchmarks used, says Navitus’s Brent Eberle.

Recent research finds that the prices of cancer drugs are rising, but the factors that contribute to the increases are difficult to pinpoint.

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

The 10 drugs selected by CMS for price negotiation are priced about three times higher in the United States than in other countries, finds a new study by the Commonwealth Fund.

CVS Caremark has entered into an agreement with AbbVie, the manufacturer of Humira, to supply Cordavis with Humira to develop a cobranded product. Cordavis is a CVS company developing private label therapies.

Zilbrysq has a list price $1,047.19 for a 23 mg syringe. It is UCB’s second treatment for patients with myasthenia gravis.

The application for afami-cell to treat patients with advanced synovial sarcoma is the first engineered T-cell therapy for solid tumors submitted to FDA.

Additionally, the FDA has approved Avzivi — the fifth biosimilar that references the cancer drug Avastin.

Zurzuvae has a list price of $15,900 for a 14-day course of treatment. No coverage information has been released.

The application for midomafetamine is the first NDA submission for any psychedelic-assisted therapy.

Eight of 10 drugs reviewed by Institute for Clinical and Economic Review were not supported by clinical evidence.

The FDA has approved the gene therapies Lyfgenia and Casgevy to treat patients with sickle cell disease. Casgevy is the first FDA-approved gene therapy to use the CRISPR gene editing technology.

The FDA has approved Lyfgenia and Casgevy to treat patients with sickle cell disease. Casgevy is the first FDA-approved gene therapy to use the CRISPR gene editing technology.

IQVIA’s Michael Kleinrock and experts at RxBenefits reveal during webinar top pharmacy trends going into 2024.

Zepbound, which was approved last month to treat obesity, is now available in U.S. pharmacies.